Gout is not associated with a lower risk of Parkinson's disease: A systematic review and meta-analysis

Parkinsonism and Related Disorders

Volumn 21, Issue 10, 2015, Pages 1238-1242

  Ungprasert, Patompong ^a,b   Srivali, Narat ^a   Thongprayoon, Charat ^a  

^a MAYO CLINIC   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Epidemiology; Gout; Meta analysis; Parkinson's disease

Indexed keywords

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; GOUT; HUMAN; INCIDENCE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SYSTEMATIC REVIEW; AGED; FEMALE; MALE; META ANALYSIS;

AGED; FEMALE; GOUT; HUMANS; MALE; PARKINSON DISEASE;

EID: 84942194468     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.08.030     Document Type: Article

References (33)

1. Zheng K.S., Dorfman B.J., Christos P.J., Khadem N.R., Henchcliffe C., Piboolnurak P., et al. Clinical characteristics of exacerbations in Parkinson disease. Neurologist 2012, 18:120-124.
2. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
3. Pringsheim T., Jette N., Frolkis A., Steeves T.D. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 2014, 29:1583-1590.
4. Yan M.H., Wang X., Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic. Biol. Med. 2013, 62:90-101.
5. Henchcliffe C., Beal M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 2008, 4:600-609.
6. Nunomura A., Moreira P.I., Lee H.G., Zhu X., Castellani R.J., Smith M.A., et al. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol. Disord. Drug Targets 2007, 6:411-423.
7. Yeum K.J., Russell R.M., Krinsky N.I., Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch. Biochem. Biophys. 2004, 430:97-103.
8. Bowman G.L., Shannon J., Frei B., Kaye J.A., Quinn J.F. Uric acid as a CNS antioxidant. J. Alzheimers Dis. 2010, 19:1331-1336.
9. Duan W., Ladenheim B., Cutler R.G., Kruman I.I., Cadet J.L., Mattson M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 2002, 80:101-110.
10. Church W.H., Ward V.L. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res. Bull. 1994, 33:419-425.
11. Davis J.W., Grandinetti A., Waslien C.I., Ross G.W., White L.R., Morens D.M. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am. J. Epidemiol. 1996, 144:480-484.
12. De Lau L.M., Koudstaal P.J., Hofman A., Breteler M.M. Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 2005, 58:797-800.
13. Weisskopf M.G., O'Reilly E., Chen H., Schwarzschild M.A., Ascherio A. Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 2007, 166:561-567.
14. Larumbe Ilundain R., Ferrer Valls J.V., Vines Rueda J.J., Guerrero D., Fraile P. Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease. Rev. Esp. Salud. Publica 2001, 75:43-53.
15. Annanmaki T., Muuronen A., Murros K. Low plasma uric acid level in Parkinson's disease. Mov. Disord. 2007, 22:1133-1137.
16. Baker J.F., Schumacher H.R. Update on gout and hyperuricemia. Int. J. Clin. Pract. 2010, 64:371-377.
17. Alonso A., Rodríguez L.A., Logroscino G. Gout and risk of Parkinson disease: a prospective study. Neurology 2007, 69:1696-1700.
18. Schernhammer E., Qiu J., Wermuth L., Lassen C.F., Friis S., Ritz B. Gout and the risk of Parkinson's disease in Denmark. Eur. J. Epidemiol. 2013, 28:359-360.
19. Lai S.W., Lin C.H., Lin C.L., Liao K.F. Gout and Parkinson's disease in older people: an observation in Taiwan. Int. J. Gerontol. 2014, 8:166-167.
20. De Vera M., Rahman M.M., Rankin J., Kopec J., Gao X., Choi H. Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum. 2008, 59:1549-1554.
21. Pakpoor J., Seminog O.O., Ramagopolan S.V., Goldacre M.J. Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: a record-linkage studies. BMC Neurol. 2015, 15:16.
22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25:603-605.
23. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin. Trial 1986, 7:177-188.
24. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
25. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
26. Euser S.M., Hofman A., Westendorp R.G., Breteler M.M. Serum uric acid and cognitive function and dementia. Brain 2009, 132:377-382.
27. Mendez-Hernandez E., Salas-Pacheco J., Ruano-Calderon L., Tellez-Valencia A., Cisneros-Martinez J., Barraza-Salas M., et al. Lower uric acid linked with cognitive dysfunction in the elderly. CNS Neurol. Disord. Drug Targets 2015, 14:564-566.
28. Liu B., Shen Y., Xiao K., Tang Y., Cen L., wei J. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol. Res. 2012, 34:163-171.
29. Billiet L., Doaty S., Katz J.D., Velasquez M.T. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol. 2014, 2014:852954.
30. Karis E., Crittenden D.B., Pillinger M.H. Hyperuricemia, gout and related comorbidities: cause and effect on a two-way street. South Med. J. 2014, 107:235-241.
31. Zhang P., Tian B. Metabolic syndrome: an important risk factor for Parkinson's disease. Oxid. Med. Cell Longev. 2014, 2014:729194.
32. Muller T., Muhlack S. Cysteinyl-glycine reduction as marker for Levodopa-induced oxidative stress in Parkinson's disease patients. Mov. Disord. 2011, 26:543-546.
33. Muller Y., Muhlack S. Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients. J. Neural. Transm. 2014, 121:643-648.